Published in Nat Rev Rheumatol on May 26, 2009
Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res (2010) 1.66
Effects of risedronate on bone marrow adipocytes in postmenopausal women. Osteoporos Int (2010) 1.51
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler Thromb Vasc Biol (2010) 1.40
The role of osteocalcin in human glucose metabolism: marker or mediator? Nat Rev Endocrinol (2012) 1.31
Lipoatrophy and severe metabolic disturbance in mice with fat-specific deletion of PPARγ. Proc Natl Acad Sci U S A (2013) 1.24
Marrow fat metabolism is linked to the systemic energy metabolism. Bone (2011) 1.23
Obesity-mediated inflammatory microenvironment stimulates osteoclastogenesis and bone loss in mice. Exp Gerontol (2010) 1.20
Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev (2010) 1.19
Why does starvation make bones fat? Am J Hum Biol (2011) 1.06
Skeletal aging and the adipocyte program: New insights from an "old" molecule. Cell Cycle (2010) 0.97
Genetic evidence that thyroid hormone is indispensable for prepubertal insulin-like growth factor-I expression and bone acquisition in mice. J Bone Miner Res (2012) 0.97
Nocturnin: a circadian target of Pparg-induced adipogenesis. Ann N Y Acad Sci (2010) 0.94
Minireview: A skeleton in serotonin's closet? Endocrinology (2010) 0.93
Ethnic and sex differences in bone marrow adipose tissue and bone mineral density relationship. Osteoporos Int (2011) 0.92
Mesenchymal stem cells, aging and regenerative medicine. Muscles Ligaments Tendons J (2012) 0.92
Bone marrow fat accumulation accelerated by high fat diet is suppressed by exercise. Bone (2014) 0.92
Gene-Lifestyle Interactions in Complex Diseases: Design and Description of the GLACIER and VIKING Studies. Curr Nutr Rep (2014) 0.91
The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes. Transl Res (2012) 0.91
A high-fat diet induces bone loss in mice lacking the Alox5 gene. Endocrinology (2011) 0.91
Circulating osteocalcin level is not associated with incident type 2 diabetes in middle-aged male subjects: mean 8.4-year retrospective follow-up study. Diabetes Care (2012) 0.88
Osteoblast-targeted suppression of PPARγ increases osteogenesis through activation of mTOR signaling. Stem Cells (2013) 0.85
New mutations at the imprinted Gnas cluster show gene dosage effects of Gsα in postnatal growth and implicate XLαs in bone and fat metabolism but not in suckling. Mol Cell Biol (2012) 0.85
Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin J Am Soc Nephrol (2010) 0.83
Association between serum osteocalcin and body mass index: a systematic review and meta-analysis. Endocrine (2017) 0.82
Importance of fat mass and lean mass on bone health in men: the Fourth Korean National Health and Nutrition Examination Survey (KNHANES IV). Osteoporos Int (2013) 0.82
RAGE supports parathyroid hormone-induced gains in femoral trabecular bone. Am J Physiol Endocrinol Metab (2009) 0.82
An adenosine receptor-Krüppel-like factor 4 protein axis inhibits adipogenesis. J Biol Chem (2014) 0.80
The Role of Bone Marrow Microenvironment in Governing the Balance between Osteoblastogenesis and Adipogenesis. Aging Dis (2015) 0.79
Peroxisome proliferator-activated receptor gamma/signal transducers and activators of transcription 5A pathway plays a key factor in adipogenesis of human bone marrow-derived stromal cells and 3T3-L1 preadipocytes. Stem Cells Dev (2011) 0.79
The effects of low dose parathyroid hormone on lumbar vertebrae in a rat model for chronic alcohol abuse. Osteoporos Int (2010) 0.79
Serum leptin levels are associated with the presence of syndesmophytes in male patients with ankylosing spondylitis. Clin Rheumatol (2012) 0.78
Increased Gs Signaling in Osteoblasts Reduces Bone Marrow and Whole-Body Adiposity in Male Mice. Endocrinology (2016) 0.77
Hormone-sensitive lipase-knockout mice maintain high bone density during aging. FASEB J (2011) 0.76
Daily leptin blunts marrow fat but does not impact bone mass in calorie-restricted mice. J Endocrinol (2016) 0.76
Biophysical Stimulation for Bone Regeneration. JSM Biotechnol Biomed Eng (2013) 0.75
Osteocalcin and the Regulation of Glucose Metabolism. Clin Rev Bone Miner Metab (2013) 0.75
Vertebral bone marrow fat, bone mineral density and diabetes: The Osteoporotic Fractures in Men (MrOS) study. Bone (2017) 0.75
Efficient isolation of bone marrow adipocyte progenitors by silica microbeads incubation. Stem Cells Dev (2013) 0.75
[Interaction between bone, fat and insulin]. Z Rheumatol (2014) 0.75
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Endocrine regulation of energy metabolism by the skeleton. Cell (2007) 10.41
Thiazolidinediones. N Engl J Med (2004) 9.42
Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell (2000) 7.87
Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci U S A (1994) 6.46
Leptin regulation of bone resorption by the sympathetic nervous system and CART. Nature (2005) 6.43
Leptin regulates bone formation via the sympathetic nervous system. Cell (2002) 5.95
PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest (2004) 5.29
Recombinant human leptin in women with hypothalamic amenorrhea. N Engl J Med (2004) 4.87
Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci U S A (2008) 4.77
Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs (2005) 4.20
The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab (2007) 4.01
Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev (1989) 3.87
PPAR-gamma regulates osteoclastogenesis in mice. Nat Med (2007) 3.59
Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care (2008) 3.45
The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int (2002) 3.45
Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPARgamma2. J Cell Biochem (1999) 3.18
Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab (2006) 3.15
Serotonin rising--the bone, brain, bowel connection. N Engl J Med (2009) 3.08
Use of thiazolidinediones and fracture risk. Arch Intern Med (2008) 2.99
Playing with bone and fat. J Cell Biochem (2006) 2.94
Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J Cell Biol (2004) 2.90
Association between serum osteocalcin and markers of metabolic phenotype. J Clin Endocrinol Metab (2008) 2.84
Leptin deficiency produces contrasting phenotypes in bones of the limb and spine. Bone (2004) 2.75
Leptin acts on human marrow stromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology (1999) 2.65
Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab (2006) 2.34
Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab (2008) 2.30
Marrow fat and the bone microenvironment: developmental, functional, and pathological implications. Crit Rev Eukaryot Gene Expr (2009) 2.26
Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res (2009) 2.20
The sympathetic tone mediates leptin's inhibition of insulin secretion by modulating osteocalcin bioactivity. J Cell Biol (2008) 2.14
Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev (2004) 2.04
Serum leptin level is a regulator of bone mass. Proc Natl Acad Sci U S A (2004) 1.99
Disruption of leptin receptor expression in the pancreas directly affects beta cell growth and function in mice. J Clin Invest (2007) 1.99
Leptin directly regulates bone cell function in vitro and reduces bone fragility in vivo. J Endocrinol (2002) 1.93
Clinical review 94: What's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab (1998) 1.93
Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept (2000) 1.91
Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol (1996) 1.90
Critical role for Ebf1 and Ebf2 in the adipogenic transcriptional cascade. Mol Cell Biol (2006) 1.86
Cloning and functional characterization of early B-cell factor, a regulator of lymphocyte-specific gene expression. Genes Dev (1993) 1.84
Fourier transform infrared microspectroscopic analysis of bones of osteocalcin-deficient mice provides insight into the function of osteocalcin. Bone (1998) 1.76
The pancreatic beta cell is a key site for mediating the effects of leptin on glucose homeostasis. Cell Metab (2006) 1.70
Leptin inhibits osteoclast generation. J Bone Miner Res (2002) 1.64
Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med (2009) 1.63
Hypoxic adipocytes pattern early heterotopic bone formation. Am J Pathol (2007) 1.62
Leptin and the sympathetic connection of fat to bone. Osteoporos Int (2007) 1.61
Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun (1996) 1.53
PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem (2009) 1.51
Beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J Bone Miner Res (2004) 1.50
Leptin is a negative independent predictor of areal BMD and cortical bone size in young adult Swedish men. J Bone Miner Res (2006) 1.46
Evidence for a dense and intimate innervation of the bone tissue, including glutamate-containing fibers. Bone (1999) 1.41
Bone remodeling, energy metabolism, and the molecular clock. Cell Metab (2008) 1.39
Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep (2004) 1.37
Dissociation of the neuronal regulation of bone mass and energy metabolism by leptin in vivo. Proc Natl Acad Sci U S A (2008) 1.34
Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm. EMBO Rep (2004) 1.33
Troglitazone treatment increases bone marrow adipose tissue volume but does not affect trabecular bone volume in mice. Calcif Tissue Int (2001) 1.32
Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin Endocrinol (Oxf) (2001) 1.30
Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat. Bone (2005) 1.28
A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab (2008) 1.26
Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology (2008) 1.26
Leptin regulates chondrocyte differentiation and matrix maturation during endochondral ossification. Bone (2005) 1.24
Molecular bases of the sympathetic regulation of bone mass. Bone (2008) 1.21
Caloric restriction decreases cortical bone mass but spares trabecular bone in the mouse skeleton: implications for the regulation of bone mass by body weight. J Bone Miner Res (2008) 1.20
Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone (2007) 1.17
TZDs and Bone: A Review of the Recent Clinical Evidence. PPAR Res (2008) 1.13
Bone abnormalities in adolescent leptin-deficient mice. Regul Pept (2006) 1.13
Serum leptin level is a predictor of bone mineral density in postmenopausal women. J Clin Endocrinol Metab (2002) 1.12
Leptin, bone mass, and the thrifty phenotype. J Bone Miner Res (2004) 1.11
Leptin reverses the inhibitory effect of caloric restriction on longitudinal growth. Endocrinology (2003) 1.10
The new field of neuroskeletal biology. Calcif Tissue Int (2007) 1.08
The influence of ghrelin, adiponectin, and leptin on bone mineral density in healthy postmenopausal women. J Bone Miner Metab (2008) 1.08
Mice lacking beta-adrenergic receptors have increased bone mass but are not protected from deleterious skeletal effects of ovariectomy. Endocrinology (2008) 1.07
Endocrine abnormalities in anorexia nervosa. Nat Clin Pract Endocrinol Metab (2008) 1.07
Pluripotential marrow cells produce adipocytes when transplanted into steroid-treated mice. Connect Tissue Res (2000) 1.06
Neuronal signaling and the regulation of bone remodeling. Cell Mol Life Sci (2005) 1.05
Life-long caloric restriction reveals biphasic and dimorphic effects on bone metabolism in rodents. Endocrinology (2007) 1.04
Leptin modulates both resorption and formation while preventing disuse-induced bone loss in tail-suspended female rats. Endocrinology (2005) 1.03
Leptin receptor genotype at Gln223Arg is associated with body composition, BMD, and vertebral fracture in postmenopausal Danish women. J Bone Miner Res (2007) 1.02
Biochemical markers of bone turnover for the clinical investigation of osteoporosis. Osteoporos Int (1993) 1.02
Surface-specific effects of a PPARgamma agonist, darglitazone, on bone in mice. Bone (2006) 1.01
Opposite effects of leptin on bone metabolism: a dose-dependent balance related to energy intake and insulin-like growth factor-I pathway. Endocrinology (2007) 1.00
Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab (2005) 0.99
Beta-blocker use and risk of fractures in men and women from the general population: the MONICA/KORA Augsburg cohort study. Osteoporos Int (2007) 0.98
Leptin predicts BMD and bone resorption in older women but not older men: the Rancho Bernardo study. J Bone Miner Res (2006) 0.97
Adrenergic control of bone remodeling and its implications for the treatment of osteoporosis. J Musculoskelet Neuronal Interact (2008) 0.96
Association between serum leptin concentrations and bone mineral density, and biochemical markers of bone turnover in adult men. J Clin Endocrinol Metab (2001) 0.95
Beta-adrenergic blockade and leptin replacement effectively mitigate disuse bone loss. J Bone Miner Res (2009) 0.94
Estrogen receptor alpha gene polymorphisms Pvu II and Xba I influence association between leptin receptor gene polymorphism (Gln223Arg) and bone mineral density in young men. Eur J Endocrinol (2002) 0.94
Dietary restriction does not adversely affect bone geometry and mechanics in rapidly growing male wistar rats. Pediatr Res (2004) 0.87
Bone mineral density and bone turnover in relation to serum leptin, alpha-ketoglutarate and sex steroids in overweight and obese postmenopausal women. Clin Endocrinol (Oxf) (2008) 0.86
Osteopenia in mice with genetic diabetes. Diabetes Res Clin Pract (1986) 0.86
Bone status in an animal model of chronic sub-optimal nutrition: a morphometric, densitometric and mechanical study. Br J Nutr (2005) 0.85
Bone mass in prepubertal boys is associated with a Gln223Arg amino acid substitution in the leptin receptor. J Clin Endocrinol Metab (2007) 0.84
Association of leptin receptor polymorphisms Lys109Arg and Gln223Arg with serum leptin profile and bone mineral density in Korean women. Am J Obstet Gynecol (2008) 0.83
Mechanism and implications of brown adipose tissue proliferation in rats and monkeys treated with the thiazolidinedione darglitazone, a potent peroxisome proliferator-activated receptor-gamma agonist. J Pharmacol Exp Ther (2003) 0.82
The effects of age and dietary restriction without nutritional supplementation on whole bone structural properties in C57BL/6J mice. Biomed Sci Instrum (1999) 0.81
Selected contribution: Bone adaptation with aging and long-term caloric restriction in Fischer 344 x Brown-Norway F1-hybrid rats. J Appl Physiol (1985) (2003) 0.80
Are serum leptin and the Gln223Arg polymorphism of the leptin receptor determinants of bone homeostasis in elderly men? Eur J Endocrinol (2006) 0.79
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab (2010) 13.29
The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med (2003) 7.25
Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc (2006) 5.32
Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem (2002) 4.52
One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med (2005) 4.03
Circulating levels of IGF-1 directly regulate bone growth and density. J Clin Invest (2002) 3.86
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med (2012) 3.34
Aging in inbred strains of mice: study design and interim report on median lifespans and circulating IGF1 levels. Aging Cell (2009) 3.16
Postmenopausal Osteoporosis. N Engl J Med (2016) 3.04
Increased bone marrow fat in anorexia nervosa. J Clin Endocrinol Metab (2009) 2.31
Deletion of the G protein-coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology (2008) 2.09
Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc (2006) 1.96
Vertebral bone marrow fat is positively associated with visceral fat and inversely associated with IGF-1 in obese women. Obesity (Silver Spring) (2010) 1.93
Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. J Clin Endocrinol Metab (2013) 1.88
Visceral fat is a negative predictor of bone density measures in obese adolescent girls. J Clin Endocrinol Metab (2010) 1.80
The 2011 Dietary Reference Intakes for Calcium and Vitamin D: what dietetics practitioners need to know. J Am Diet Assoc (2011) 1.80
Continuing bisphosphonate treatment for osteoporosis--for whom and for how long? N Engl J Med (2012) 1.79
Congenic strains of mice for verification and genetic decomposition of quantitative trait loci for femoral bone mineral density. J Bone Miner Res (2003) 1.78
Adolescent girls in Maine are at risk for vitamin D insufficiency. J Am Diet Assoc (2005) 1.74
Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res (2002) 1.73
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis. Nat Rev Endocrinol (2010) 1.72
Ovariectomy-induced bone loss varies among inbred strains of mice. J Bone Miner Res (2005) 1.70
Mechanical stimulation of mesenchymal stem cell proliferation and differentiation promotes osteogenesis while preventing dietary-induced obesity. J Bone Miner Res (2009) 1.67
Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J Bone Miner Res (2010) 1.66
Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 1.65
Moderate alcohol intake lowers biochemical markers of bone turnover in postmenopausal women. Menopause (2012) 1.63
Marrow fat and bone--new perspectives. J Clin Endocrinol Metab (2013) 1.60
Late-life rapamycin treatment reverses age-related heart dysfunction. Aging Cell (2013) 1.60
Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology (2005) 1.58
Lack of association between adipose tissue distribution and IGF-1 and IGFBP-3 in men and women. Cancer Epidemiol Biomarkers Prev (2002) 1.57
What's the matter with MAT? Marrow adipose tissue, metabolism, and skeletal health. Ann N Y Acad Sci (2014) 1.54
Bicc1 is a genetic determinant of osteoblastogenesis and bone mineral density. J Clin Invest (2014) 1.53
Mapping quantitative trait loci for vertebral trabecular bone volume fraction and microarchitecture in mice. J Bone Miner Res (2003) 1.52
PPARgamma2 nuclear receptor controls multiple regulatory pathways of osteoblast differentiation from marrow mesenchymal stem cells. J Cell Biochem (2009) 1.51
PPARG by dietary fat interaction influences bone mass in mice and humans. J Bone Miner Res (2008) 1.50
Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov (2011) 1.48
A circadian-regulated gene, Nocturnin, promotes adipogenesis by stimulating PPAR-gamma nuclear translocation. Proc Natl Acad Sci U S A (2010) 1.46
Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab (2013) 1.45
Bone density in ambulatory and immobile children. J Clin Densitom (2002) 1.43
The ternary IGF complex influences postnatal bone acquisition and the skeletal response to intermittent parathyroid hormone. J Endocrinol (2006) 1.37
Genetic effects for femoral biomechanics, structure, and density in C57BL/6J and C3H/HeJ inbred mouse strains. J Bone Miner Res (2003) 1.37
Determinants of bone mineral density in obese premenopausal women. Bone (2010) 1.36
Bone marrow changes in adolescent girls with anorexia nervosa. J Bone Miner Res (2010) 1.35
Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D. J Bone Miner Res (2005) 1.34
Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo. J Bone Miner Res (2002) 1.28
Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology (2008) 1.26
Genetic dissection of mouse distal chromosome 1 reveals three linked BMD QTLs with sex-dependent regulation of bone phenotypes. J Bone Miner Res (2007) 1.26
Physiologic regulators of bone turnover in young women with anorexia nervosa. J Pediatr (2002) 1.25
Transgenic mice with osteoblast-targeted insulin-like growth factor-I show increased bone remodeling. Bone (2006) 1.25
Altered metabolism and lipodystrophy in the early B-cell factor 1-deficient mouse. Endocrinology (2010) 1.24
Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J Bone Miner Res (2005) 1.23
Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J (2008) 1.23
Effects of GH in women with abdominal adiposity: a 6-month randomized, double-blind, placebo-controlled trial. Eur J Endocrinol (2012) 1.21
Growth hormone regulates the balance between bone formation and bone marrow adiposity. J Bone Miner Res (2010) 1.20
Novel insights into the relationship between diabetes and osteoporosis. Diabetes Metab Res Rev (2010) 1.19
Inducible brown adipose tissue, or beige fat, is anabolic for the skeleton. Endocrinology (2013) 1.18
Preadipocyte factor-1 is associated with marrow adiposity and bone mineral density in women with anorexia nervosa. J Clin Endocrinol Metab (2009) 1.18
Young women with cold-activated brown adipose tissue have higher bone mineral density and lower Pref-1 than women without brown adipose tissue: a study in women with anorexia nervosa, women recovered from anorexia nervosa, and normal-weight women. J Clin Endocrinol Metab (2012) 1.18
Quantitative trait loci that determine BMD in C57BL/6J and 129S1/SvImJ inbred mice. J Bone Miner Res (2005) 1.17
Postnatal growth and bone mass in mice with IGF-I haploinsufficiency. Bone (2006) 1.16
Vertebral bone marrow fat associated with lower trabecular BMD and prevalent vertebral fracture in older adults. J Clin Endocrinol Metab (2013) 1.16
Effects of oral dehydroepiandrosterone on bone density in young women with anorexia nervosa: a randomized trial. J Clin Endocrinol Metab (2002) 1.14
The insulin-like growth factor-I gene and osteoporosis: a critical appraisal. Gene (2005) 1.12
Elevated serum levels of IGF-1 are sufficient to establish normal body size and skeletal properties even in the absence of tissue IGF-1. J Bone Miner Res (2010) 1.12
Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. J Clin Endocrinol Metab (2011) 1.11
PERK eIF2alpha kinase regulates neonatal growth by controlling the expression of circulating insulin-like growth factor-I derived from the liver. Endocrinology (2003) 1.11
Marrow fat and preadipocyte factor-1 levels decrease with recovery in women with anorexia nervosa. J Bone Miner Res (2012) 1.11
Quantitative trait loci for BMD in an SM/J by NZB/BlNJ intercross population and identification of Trps1 as a probable candidate gene. J Bone Miner Res (2008) 1.10
A missense mutation in the mouse Col2a1 gene causes spondyloepiphyseal dysplasia congenita, hearing loss, and retinoschisis. J Bone Miner Res (2003) 1.09
Impact of seafood and fruit consumption on bone mineral density. Maturitas (2006) 1.07
Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med (2003) 1.07
From mouse to man: redefining the role of insulin-like growth factor-I in the acquisition of bone mass. Exp Biol Med (Maywood) (2003) 1.07
The role of circulating IGF-I: lessons from human and animal models. Endocrine (2002) 1.05
Serum IGF-1 affects skeletal acquisition in a temporal and compartment-specific manner. PLoS One (2011) 1.04
The many facets of PPARgamma: novel insights for the skeleton. Am J Physiol Endocrinol Metab (2010) 1.04
Change in undercarboxylated osteocalcin is associated with changes in body weight, fat mass, and adiponectin: parathyroid hormone (1-84) or alendronate therapy in postmenopausal women with osteoporosis (the PaTH study). J Clin Endocrinol Metab (2011) 1.03
Paracrine overexpression of IGFBP-4 in osteoblasts of transgenic mice decreases bone turnover and causes global growth retardation. J Bone Miner Res (2003) 1.03
The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem (2011) 1.02
Insulin-like growth factor-I and bone: lessons from mice and men. Pediatr Nephrol (2008) 1.01
The effect of gonadal and adrenal steroid therapy on skeletal health in adolescents and young women with anorexia nervosa. Metabolism (2012) 1.01
Nocturnin suppresses igf1 expression in bone by targeting the 3' untranslated region of igf1 mRNA. Endocrinology (2010) 1.00
Genetic increase in serum insulin-like growth factor-I (IGF-I) in C3H/HeJ compared with C57BL/6J mice is associated with increased transcription from the IGF-I exon 2 promoter. Endocrinology (2006) 1.00
Impact of pregnancy-associated plasma protein-a deletion on the adult murine skeleton. J Bone Miner Res (2008) 0.99
Perturbations in bone formation and resorption in insulin-like growth factor binding protein-3 transgenic mice. J Bone Miner Res (2003) 0.99
Altered thermogenesis and impaired bone remodeling in Misty mice. J Bone Miner Res (2013) 0.99
In osteoporosis, differentiation of mesenchymal stem cells (MSCs) improves bone marrow adipogenesis. Biol Res (2012) 0.98
The IGF-I regulatory system and its impact on skeletal and energy homeostasis. J Cell Biochem (2010) 0.98
Elevated serum IGF-1 levels synergize PTH action on the skeleton only when the tissue IGF-1 axis is intact. J Bone Miner Res (2010) 0.98
Insulin-like growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphatase β and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol (2012) 0.97
Skeletal aging and the adipocyte program: New insights from an "old" molecule. Cell Cycle (2010) 0.97
A novel spontaneous mutation of Irs1 in mice results in hyperinsulinemia, reduced growth, low bone mass and impaired adipogenesis. J Endocrinol (2009) 0.97
Sprouty1 is a critical regulatory switch of mesenchymal stem cell lineage allocation. FASEB J (2010) 0.97
The transcription factor paired-related homeobox 1 (Prrx1) inhibits adipogenesis by activating transforming growth factor-β (TGFβ) signaling. J Biol Chem (2012) 0.96
Insulin-like growth factor-binding protein-2 is required for osteoclast differentiation. J Bone Miner Res (2012) 0.95
Temperatures rising: brown fat and bone. Discov Med (2011) 0.95
Epithelial-specific and stage-specific functions of insulin-like growth factor-I during postnatal mammary development. Endocrinology (2006) 0.95
Postmenopausal Osteoporosis. N Engl J Med (2016) 0.95
Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling. J Clin Endocrinol Metab (2008) 0.94
A dual-radioisotope hybrid whole-body micro-positron emission tomography/computed tomography system reveals functional heterogeneity and early local and systemic changes following targeted radiation to the murine caudal skeleton. Calcif Tissue Int (2014) 0.94
Nocturnin: a circadian target of Pparg-induced adipogenesis. Ann N Y Acad Sci (2010) 0.94